Wilmer Cutler Pickering Hale and Dorr represented Telix Pharmaceuticals Limited in the transaction. Telix Pharmaceuticals Limited (ASX: TLX) (Telix), a biopharmaceutical company, announced its acquisition of...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Navient Corporation in the offering. Navient Corporation (Nasdaq: NAVI), a provider of technology-enabled education finance and business processing solutions,...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis represented Linden Capital Partners, Wilmer Cutler Pickering Hale and Dorr represented Alcresta Therapeutics and Wilson Sonsini Goodrich & Rosati advised HealthQuest Capital. Linden...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented TechTarget, Inc. in the transaction, and Clifford Chance represented Informa PLC. TechTarget, Inc. (NASDAQ: TTGT) and Informa PLC (LSE:...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Sierra Space on the transaction. Sierra Space announced that it closed a $290 million Series B funding round. The round brings...
You must be a Standard 1 Year member to access this content.
WilmerHale represented Blue Apron in the transaction. Blue Apron (NYSE: APRN), an American ingredient-and-recipe meal kit company, announced the signing and closing of a transaction with...
You must be a Standard 1 Year member to access this content.
Latham & Watkins served as legal advisor to Basalt in the transaction, while Wilmer Cutler served as legal advisor to SDC Capital Partners. Basalt Infrastructure Partners...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Voyager Therapeutics on the deal. Voyager Therapeutics announced that it entered into a strategic collaboration agreement with Neurocrine Biosciences...
You must be a Standard 1 Year member to access this content.
